Trellis Vitality Tirzepatide Review: $199/Month, and the Pricing It Says It Publishes (2026)

Trellis Vitality charges $199 a month for compounded tirzepatide on a one-month plan, $189 a month on three, and $179 a month on six — printed as an ordinary table on the product page, with the one-month column labeled as the one-month column and a note that every dosage costs the same. After a few hundred of these reviews we can say plainly that this is what a price ladder is supposed to look like, and that most of this industry does not manage it. This page carries no outbound link; every figure below comes from Trellis's own pages, read August 2026.

The tirzepatide table

Three things make this table worth more than the numbers in it. First, the one-month column is explicitly month-to-month — it is not a total divided by a term, which is how most "from $179" claims in this category are manufactured. Second, the price does not move with the dose: the page says all dosages are available at the same price, so a titration to 12.5 mg does not silently reprice your plan in month four. Third, the discount for committing is small and honest — $20 a month to go from one month to six, about 10%, rather than the 30% gap you see where the headline number is really an annual prepay.

Semaglutide runs on the same structure at $150, $140 and $133. Tirzepatide's $49-a-month premium over semaglutide is roughly what the molecule difference costs across the field; our tirzepatide vs semaglutide comparison covers what you get for it.

What is not published, despite the claim that it is

Trellis sells four other things: NAD+, glutathione, lipo-MIC with B12, and tesamorelin. For all four, the entire price disclosure is a single "treatment plans starting at" figure — $129, $93, $130 and $299 respectively. There is no rung table for any of them. We pulled the site's compiled front-end bundle, the rendered pages, and the intake payload behind the NAD+ consultation flow, and none of the three contains a product price ladder. NAD+ is the company's flagship product and its price structure is not public.

That matters because of what the company says about itself. Trellis's own blog, in a post about NAD+ injection cost updated in July 2026, states twice that Trellis publishes its complete pricing on its program pages. It does not. It publishes one floor number and a consultation button.

And the floor number is probably not a monthly rate. Look at the shape of the GLP-1 table: the six-month rung sits about 10% below the one-month rung. If the same structure sits behind NAD+, then $129 is the bottom of a ladder and the month-to-month price is higher. That is an inference, not an observation, and we are not going to publish it as a fact — but it is the reason we will not file $129 as Trellis's monthly NAD+ price, and neither should anyone else. Ask for the one-month figure before you book.

Who prescribes it

The medical group is Arora Health & Aesthetics, LLC, medical director Dr. Sean Arora, NPI 1841729449 — active, Seattle, family medicine, when checked against the national registry.³

**That is the same medical group and the same medical director as The Edit, which charges $309 a month for the same molecule. The two run different pharmacies and different price sheets and are genuinely separable products, so the $110 gap is real and Trellis is on the right side of it. But they are not two independent clinical organizations**, and if you are shortlisting both in order to get a second opinion on the first, you will not get one.

The pharmacy, named

VialsRX, a state-licensed compounding pharmacy in Houston, Texas — named in the machine-readable summary Trellis publishes for AI crawlers, which is an odd place to put it but a real disclosure nonetheless. Two others in the same batch, Pepti and Auren Rx, each name one as well — and like Trellis, neither states whether its pharmacy is a 503A or a 503B facility.

What we could not verify

No legal entity. The terms page runs about three kilobytes of text and never names an LLC or corporation behind the Trellis Vitality brand. Every other provider in this batch names one, even when the address turns out to be a registered-agent suite.

The fee position is stated but not documented. Product pages promise no membership, no consultation cost, and a free vitality assessment. We found nothing contradicting that — but we also found no terms document substantial enough to corroborate it, which is a different thing from finding it confirmed.

The marketing numbers are unsourced. A 4.7-out-of-5 rating, more than five thousand current patients, an average of 3.4 weeks saved, and $4,000 in average annual patient savings all appear on the site with no source, no methodology and no review count anywhere behind them. We are recording that they are claimed and declining to repeat them as findings.

States and the regulatory screen

Trellis says it operates in all 50 states, via board-certified physicians, in both its product-page badges and its crawler summary — and on 1 September 2026 its own GLP-1 FAQ said something narrower: that the program is not offered in every state, naming Connecticut, Ohio and South Carolina as suppressed "at minimum", with no list of the rest. The brand name, the medical group and the named pharmacy all returned zero company-column matches in the FDA's live warning-letter index in August 2026.² The screen ran with a positive control that correctly surfaced a real February 2026 letter to an unrelated telehealth seller every time,⁴ so a zero here means a zero.

Brand versus compounded

This is compounded tirzepatide, not Zepbound — pharmacy-made, not an FDA-approved finished drug, and not the product studied in the pivotal trials. See is compounded tirzepatide still legal in 2026 for where that stands. The molecule's own evidence is strong and separate from the seller: about 15% to 21% average body-weight loss over 72 weeks in SURMOUNT-1⁵, and about 20% versus 14% against semaglutide in SURMOUNT-5⁶. Our tirzepatide evidence guide has the rest.

The honest verdict

For tirzepatide specifically, Trellis is one of the cleanest buys we have looked at this year: $199 a month with no commitment, no dose-indexed increase, no prepay disguised as a rate, and a named compounder. The problems are all outside the GLP-1 shelf — a flagship NAD+ product whose price structure is invisible, a blog claiming a transparency the site does not deliver, a company with no published legal name, and a set of impressive statistics nobody can check. None of that changes the tirzepatide number, and the tirzepatide number is the reason to be here. Just do not let "they publish complete pricing" carry over from the GLP-1 page to anything else on the menu, and remember that The Edit is not an independent second opinion. Compare the rung against the rest of the field in our tirzepatide price index or the ranked best tirzepatide providers ranking.